Hepatitis C can be Cured

Two Companies: Gilead Sciences & Bristol-Myers; Two Drugs: Daclatasvir+GS-7977 (now called sofosbuvir); One Cure: For Hepatitis C without Interferon or Ribavirin The HCV Coalition for the Cure (HCVCC) is a grassroots organization dedicated to making a cure for Hepatitis C a reality for the millions of people affected by this disease.

Quoting from ETAG: "The most effective new therapy for hepatitis C -- two pills that could cure nearly every patient treated -- may never see the light of day because the developers of these new medicines, Bristol-Myers Squibb and Gilead Sciences, seem unable to work together. Apparently, profits are more important than best patient care. Best therapy combines Bristol's daclatasvir with Gilead's GS-7977 (now called sofosbuvir). Each is a single pill administered once a day. The results from this new therapy are nothing short of spectacular -- an early cure rate of 100% for genotypes 1, 2, 3, according to data from a mid-stage study announced Thursday at the European Association for the Study of Liver Disease (EASL) meeting. Amazingly, this most promising new treatment for hepatitis C patients may actually be discontinued because Bristol and Gilead can't work together. Gilead needs to justify that $11 billion and deliver profits and returns to its shareholders. Collaborating with Bristol would more than likely dilute Gilead's Hep C profits, which helps explain why Gilead isn't exactly thrilled to push ahead. Hep C patients in need of convenient and potent new cures are being hurt." Please sign this petition to urge Gilead to work with Bristol-Myers Squibb on this drug combination for the benefit of those suffering with hepatitis C.